A new, rapid, accurate, precise High-performance thin layer chromatographic (HPTLC) method was developed for the simultaneous estimation of Montelukast sodium and Rupatidine fumarate in pharmaceutical dosage forms. Estimation was performed on TLC aluminum plates precoated with silica gel 60F-254 as stationary phase. Linear ascending development was carried out in twin trough glass chamber saturated with mobile phase consisting of Toluene: Ethyl acetate: methanol (5:3: 2v/v) at room temperature (25 ± 2 0C). After development of the plate, Camag TLC scanner 4 (scanning speed 20mm sec-1 and data resolution 100μm/step) was used for spectrodensitometric scanning with win CATS software (slit-micro, 6 x 0.30 mm). Analysis of the plate in absorbance mode at 280 nm was carried out. The system was found to give compact spots for Montelukast sodium and Rupatidine fumarate with Rf. (Retardation factor) value of 0.61± 0.02 and 0.45± 0.03 respectively. The data for calibration plots showed good linear relationship with correlation coefficient of 0.99875 and 0.99796 in the concentration range of 0.2-1.4 and 1.4-9.8 μg/spot for Montelukast sodium and Rupatidine fumarate respectively. The present method was validated according to the ICH guidelines.
Introduction

Standard solutions
It was used stock solutions each of Montelukast sodium were 10mg-in 10 ml methanol. Rupatidine fumarate (2 μL) were 10mg-in 5 ml methanol. The binary mixture containing 10and 10 mg of Montelukast sodium and Rupatidine fumarate. Montelukast sodium (0.2 μL) was prepared by transferring 1 ml from respective stock solutions to a 5mL volumetric flask and make up with methanol.
Chromatographic Condition
Chromatographic separation was performed on Merck TLC plates precoated with silica gel 60 F 254 . The samples were applied onto the plates as a band with 8 mm width using Camag 100 microlitre sample syringe (Hamilton, Switzerland) with a Camag Linomat 5 applicator (Camag, Switzerland).
Linear ascending development was carried out in a twin trough glass chamber (20 x 10 cm) with the mobile phase Toluene: Ethyl acetate: methanol (5:3: 2v/v). Mobile phase was developed by trial and error method. Scanning was performed using Camag TLC scanner 4 at 280 nm and operated by winCATS software (V 1.4.6 Camag). Ultrasonicator was used for extraction of the drugs from the Tablet. Preparation of Standard and Sample Solution 10 mg of each Montelukast sodium and Rupatidine fumarate were weighed separately and transferred in two different 10 ml volumetric flasks. These drugs were dissolved in 5 ml of methanol solvent by vigorous shaking and then volume was made up to mark with methanol to obtained final concentration of 1 mg/ml of each component. Out of that 1 ml was pipette out and transferred to 10 ml volumetric flask and volume was made up to mark with methanol to get 100 µg/ml solutions. Combination of standards was prepared by taking in 1:1 proportion from both solutions. 276.4 mg Tablet were weighed and transferred into another volumetric flask containing 50 ml of methanol and kept in ultrasonicator for 20 minutes for extraction of drugs from Tablet. From resulting solution 1 ml of solution was withdrawn and transferred in 10 ml volumetric flask and then volume was made up to the mark with methanol to obtained final concentration of 0.2 mg/ml.
Method Validation
Method was validated and carried out as per the ICH guidelines [21] . The parameters checked were precision, reproducibility, limit of detection, limit of quantification and recovery.
Calibration Curves of Montelukast sodium and Rupatidine fumarate
A stock solution of Montelukast sodium and Rupatidine fumarate (0.2 µg/ml& 2µg/ml) was prepared in methanol. Out of that 1 ml was pipette out and transferred to 10 ml volumetric flask and volume was made up to mark with methanol to get 100 µg/ml solution. 
Method Validation
The measurement of the peak area showed low values of S.E. and % R.S.D. (<1%) for inter-and intra-day variation, which suggested an excellent precision of the method ( Table 2) Table 2 ). The formulation was analyzed and found to contain 4.36µg of montelukast sodium and 0.57µg of Rupatidine in a tablet (Table 3) . In recovery studies the analyzed samples were spiked with extra 80, 100, 120% of the standard montelukast sodium and Rupatidine fumarate and the mixtures were reanalyzed by the proposed method.
The experiment was conducted in triplicate. This was done to check for the recovery of the drug at different levels in the formulation. The proposed method when used for extraction and subsequent estimation of curcumin and gallic acid from the formulation afforded recovery of 98.8%, 99.19%, 102.6% and 89.69%, 89.70%, 88.2% respectively as listed in (Table 6 ). The peak purity of montelukast sodium and Rupatidine fumarate was assessed by comparing the spectra at peak start, peak apex and peak end positions of the spot as shown in graph 1, 2 and 3. Good correlation was obtained between the standard and the sample overlain spectra of montelukast sodium (Table  7) .
Analysis of the Formulation
Montelukast sodium and rupatudine fumarate from tablet formulation showed single spots at Rf = 0.61 ± 0.02 and 0.45 ± 0.03 respectively (Figure 3) . The % of Montelukast sodium and rupatudine fumarate from tablet was found to be 96.66 and 114% and was well within the limits. By considering Rf values of standard Montelukast sodium and rupatudine fumarate and spots observed of samples, fingerprint analysis, presence of these active chemical marker compounds was detected. 
Conclusion
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